Today: 28 June 2026
Browse Category

NYSE:BMY 24 December 2025 - 15 June 2026

Replimune jumps 85% after FDA opens up third dose for skin cancer therapy

Replimune jumps 85% after FDA opens up third dose for skin cancer therapy

Replimune Group shares soared 85% to $8.64 Friday after the company said it will resubmit its advanced melanoma drug RP1 to the FDA, which agreed to a priority review. The FDA had rejected the therapy in April, citing lack of a control group. Replimune plans to file again within days and will present new trial data at an oncology meeting May 30. Bristol Myers fell 0.6%, while Iovance dropped 6.5%.
29 May 2026
··
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft shares fell 1.1% to $454.52 in after-hours trading Tuesday, tracking a broad tech selloff as tariff concerns rattled markets. Bristol Myers Squibb announced a partnership to use Microsoft’s AI radiology tools for early lung cancer detection. Investors are awaiting Microsoft’s fiscal Q2 earnings on Jan. 28 for updates on cloud and AI growth. The S&P 500 closed down 2.04%, Nasdaq off 2.38%.
20 January 2026
···
Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia dropped 3.4% to $179.83, dragging AI stocks lower as U.S. markets fell on tariff threats from President Trump over Greenland. The Nasdaq lost 1.6% and S&P 500 slid 1.3% in early trading. Morgan Stanley downgraded IT hardware, citing weak demand and high costs. Microsoft, Broadcom, and Palantir also declined, while AMD rose 1.3%.
20 January 2026
············
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb shares jumped 4.2% to $56.72 after UBS upgraded the stock to “buy” and raised its price target to $65. UBS cited upcoming catalysts but noted ongoing patent-expiry pressure through 2028. Trading volume exceeded averages as the stock outperformed peers on a down market day. Investors await the company’s Jan. 12 J.P. Morgan conference appearance and Feb. 5 quarterly results.
8 January 2026
·
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb shares fell 0.7% to $54.27 in thin year-end trading Monday, underperforming the broader U.S. market. Investors are watching the Jan. 2 shareholder record date for its next dividend and the Feb. 5 earnings report. Peers were mixed, with Eli Lilly up and Pfizer down. Low volumes and year-end rebalancing drove volatility, according to traders.
29 December 2025
···
Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers Squibb shares closed down 0.1% at $54.64 Friday, trading in a narrow range as year-end positioning and Fed rate signals dominated market focus. The company’s next investor event is its fourth-quarter results call on Feb. 5. Thin holiday trading volume heightened volatility across sectors. The S&P 500 hovered near 7,000, with investors watching for signs of momentum shifts.
29 December 2025
·
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb closed Friday at $54.64, down 0.13%, with after-hours indications at $54.75 late Saturday. Institutional filings showed Brookstone Capital Management and Cwm LLC increased stakes, while Meyer Handelman Co. reduced holdings. The stock sits in the middle of its $42.52–$63.33 52-week range. Analyst consensus remains mixed, with an average price target near $53.93.
28 December 2025
·
Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb shares closed Friday at $54.65, little changed, and edged up to $54.72 after hours. The stock is down about 3% for 2025, trading near the lower end of its yearly range. Recent headlines focused on institutional position changes and year-end market conditions, with light news flow as U.S. markets head into the weekend.
27 December 2025
···
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) closed Friday at $54.64, down 0.13%, with after-hours trading near $54.72. Institutional filings showed mixed moves: Meyer Handelman Co. cut its stake by 9.9%, while Cwm LLC and Brookstone Capital Management increased holdings. No major company news released in the past 48 hours. Trading volume reached about 9.57 million shares.
27 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb closed at $54.71 on Dec. 24, 2025, after trading between $54.20 and $54.75, with a 52-week range of $42.52 to $63.33. The company agreed to provide Eliquis free to Medicaid starting in 2026 and will donate over seven tons of Eliquis API to the U.S. government. BMS also announced steep discounts for several drugs and secured three years of tariff relief.
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb closed at $54.71 on Dec. 24, up 0.79%, with after-hours trading flat at $54.70 amid thin holiday volume. The NYSE session ended early for Christmas Eve. Analysts cited by MarketBeat maintained a “Hold” consensus and average 12-month target near current levels. No major company news moved the stock.
25 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb closed at $54.26 Tuesday, down 0.74%, then edged up to $54.36 after hours. The move followed news that Bristol Myers and Johnson & Johnson asked the U.S. Supreme Court to review Medicare drug price negotiations under the Inflation Reduction Act. Trading volume reached about 16.6 million shares. The stock sits roughly midway between its 52-week high and low.
24 December 2025
·
1 2 3

Stock Market Today

  • AbraSilver Resource Posts New Diablillos DFS, Stock Valuation Debated
    June 28, 2026, 3:44 PM EDT. AbraSilver Resource (TSX:ABRA) released a new Definitive Feasibility Study (DFS) for its Diablillos project, updating investors on mine plan metrics and reserves. The stock recently traded at CA$14.46, showing volatility with a mix of short-term gains and a 21.5% decline over one month. Analysts note the company's Price to Book (P/B) ratio of 33.9x is low compared to its peer group average of 144.2x, suggesting relative value within early-stage metal exploration. However, this P/B is high against the broader Canadian mining sector average of 2.6x, reflecting market optimism driven by project prospects despite AbraSilver's CA$62.56 million operating losses and reliance on high-risk funding. Investor sentiment remains mixed on whether the stock price fairly accounts for future growth risks and rewards.

Latest articles

Go toTop